Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

NCT02201199 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: insulin glargine U200 HOE901
DRUG: insulin glargine U500 HOE901
DRUG: insulin glargine U100 HOE901

Sponsor

Sanofi